Literature DB >> 12651869

E-box mutations in the RAPSN promoter region in eight cases with congenital myasthenic syndrome.

Kinji Ohno1, Menachem Sadeh, Ilan Blatt, Joan M Brengman, Andrew G Engel.   

Abstract

Myogenic determination factors are basic helix-loop-helix proteins that govern specification and differentiation of muscle cells, and bind to the E-box consensus sequence CANNTG in promoter regions of muscle-specific genes. No E-box mutation has been reported to date. RAPSN encodes rapsyn, a 43 kDa postsynaptic peripheral membrane protein that clusters the nicotinic acetylcholine receptor at the motor endplate. Transcriptional regulation mechanisms of RAPSN have not been studied. We here report two novel E-box mutations in the RAPSN promoter region in eight congenital myasthenic syndrome patients. Patient 1 carries -27C-->G that changes an E-box at -27 to -22 from CAGCTG to GAGCTG. An allele harboring -27C-->G is not transcribed in patient's muscle. Patients 2-8 are of Oriental Jewish stock of Iraqi or Iranian origin with facial malformations, and harbor -38A-->G that changes another E-box at -40 to -35 from CAACTG to CAGCTG, which does not affect the consensus CANNTG sequence. Haplotype analysis shows that -38A-->G arises from a common founder. For each mutation, position +1 represents the major transcriptional start site that we determine to be 172 nucleotides upstream of the translational start site. Electrophoretic mobility shift assays reveal that -38A-->G gains, and -27C-->G looses, binding affinity for different components of nuclear extracts of C2C12 myotubes. Luciferase reporter assays show that both -38A-->G and -27C-->G attenuate reporter gene expression in C2C12 myotubes, and that -27C-->G additionally attenuates reporter gene expression in MyoD- or myogenin-transfected HEK cells. The -27C-->G mutation also markedly attenuates the enhancer activity of an E-box on an SV40 promoter. Impaired transcriptional activities of the RAPSN promoter region predict reduced rapsyn expression and endplate acetylcholine receptor deficiency.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12651869     DOI: 10.1093/hmg/ddg089

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  23 in total

1.  Nuclear factor kappaB controls acetylcholine receptor clustering at the neuromuscular junction.

Authors:  Jia Wang; Xiu-Qing Fu; Wen-Liang Lei; Tong Wang; Ai-Li Sheng; Zhen-Ge Luo
Journal:  J Neurosci       Date:  2010-08-18       Impact factor: 6.167

2.  Fgfr4 is required for effective muscle regeneration in vivo. Delineation of a MyoD-Tead2-Fgfr4 transcriptional pathway.

Authors:  Po Zhao; Giuseppina Caretti; Stephanie Mitchell; Wallace L McKeehan; Adele L Boskey; Lauren M Pachman; Vittorio Sartorelli; Eric P Hoffman
Journal:  J Biol Chem       Date:  2005-11-02       Impact factor: 5.157

3.  Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis.

Authors:  Pilar Martínez-Martínez; Mario Losen; Hans Duimel; Peter Frederik; Frank Spaans; Peter Molenaar; Angela Vincent; Marc H De Baets
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

Review 4.  Receptor-associated proteins and synaptic plasticity.

Authors:  Emile G Bruneau; Jose A Esteban; Mohammed Akaaboune
Journal:  FASEB J       Date:  2008-10-31       Impact factor: 5.191

Review 5.  The role of homeodomain transcription factors in heritable pituitary disease.

Authors:  Kelly L Prince; Emily C Walvoord; Simon J Rhodes
Journal:  Nat Rev Endocrinol       Date:  2011-07-26       Impact factor: 43.330

Review 6.  Current status of the congenital myasthenic syndromes.

Authors:  Andrew G Engel
Journal:  Neuromuscul Disord       Date:  2011-11-21       Impact factor: 4.296

7.  Common founder effect of rapsyn N88K studied using intragenic markers.

Authors:  Vanessa Dunne; Ricardo A Maselli
Journal:  J Hum Genet       Date:  2004-06-08       Impact factor: 3.172

8.  Myasthenic syndrome due to defects in rapsyn: Clinical and molecular findings in 39 patients.

Authors:  M Milone; X M Shen; D Selcen; K Ohno; J Brengman; S T Iannaccone; C M Harper; A G Engel
Journal:  Neurology       Date:  2009-07-21       Impact factor: 9.910

Review 9.  WNTs tune up the neuromuscular junction.

Authors:  Ceren Korkut; Vivian Budnik
Journal:  Nat Rev Neurosci       Date:  2009-09       Impact factor: 34.870

10.  Muscle-like nicotinic receptor accessory molecules in sensory hair cells of the inner ear.

Authors:  Abdullah A Osman; Angela D Schrader; Aubrey J Hawkes; Omar Akil; Adam Bergeron; Lawrence R Lustig; Dwayne D Simmons
Journal:  Mol Cell Neurosci       Date:  2008-03-04       Impact factor: 4.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.